Navigation Links
Cephalon's 2007 Results Exceed Full Year Sales and Earnings Guidance
Date:2/12/2008

46,630 - 46,630

FENTORA 29,250 - 29,250

AMRIX - - -

Pain 176,762 8,039 184,801

Other 14,423 55,841 70,264

$394,828 $78,519 $473,347

%

Increase

(Decrease)

United

States Europe Total

Sales:

PROVIGIL 9% (19%) 7%

GABITRIL (15%) (50%) (18%)

CNS 8% (21%) 6%

ACTIQ (58%) 50% (50%)

Generic OTFC (33%) 0% (33%)

FENTORA 16% 0% 16%

AMRIX 100% 0% 100%

Pain (34%) 50% (31%)

Other 7% 17% 15%

(11%) 13% (7%)

Year Ended

December 31,

2007

United

States Europe Total

Sales:

PROVIGIL $801,639 $50,408 $852,047

GABITRIL 50,642 6,668 57,310

CNS 852,281 57,076 909,357

ACTIQ
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
4. CNS Response Announces Fiscal Third Quarter 2007 Results
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Carrington Reports Second Quarter 2007 Results
9. Avitar Reports Third Quarter Financial Results for Fiscal 2007
10. Response Genetics Reports Second Quarter 2007 Financial Results
11. Martek to Announce Third Quarter 2007 Results on September 5, 2007
Post Your Comments:
*Name:
*Comment:
*Email: